PCSK9 inhibitor
PCSK9 inhibitor is a pharmaceutical drug with 17 clinical trials. Currently 7 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
7
trials recruiting
17
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques
Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study
Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
Clinical Trials (17)
The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques
Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study
Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)
Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients
Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography
Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)
Exploratory Research of PCSK9 Inhibitor on Patency of aAVF After PTA With PCB
Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors
Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study
Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome
All 17 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 17